TY - JOUR
T1 - Serum uric acid lowering with empagliflozin in heart failure with reduced ejection fraction
T2 - a sweet added benefit?
AU - Mackenzie, Isla S.
AU - MacDonald, Thomas M.
N1 - Publisher Copyright:
© TheAuthor(s) 2022. Published by Oxford University Press on behalf of European Society of Cardiology. All rights reserved. For permissions, please e-mail: [email protected].
PY - 2022/9/21
Y1 - 2022/9/21
N2 - This editorial refers to ‘Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial’, by W. Doehner et al., https://doi.org/10.1093/eurheartj/ehac320.
AB - This editorial refers to ‘Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial’, by W. Doehner et al., https://doi.org/10.1093/eurheartj/ehac320.
UR - http://www.scopus.com/inward/record.url?scp=85138247547&partnerID=8YFLogxK
U2 - 10.1093/eurheartj/ehac415
DO - 10.1093/eurheartj/ehac415
M3 - Editorial
C2 - 35938377
SN - 0195-668X
VL - 43
SP - 3447
EP - 3449
JO - European Heart Journal
JF - European Heart Journal
IS - 36
ER -